ADVANCE and ADVANCE-ON studies – benefits from perindopril and indapamide therapy in patients with diabetes Review article
Article Sidebar
Main Article Content
Abstract
In the ADVANCE study, benefits from fixed-dose combination therapy with perindopril and indapamide were shown in patients with diabetes type 2 regardless of baseline blood pressure values, the diagnosis of hypertension, and concomitant use of other antihypertensive drugs. During more than 4 years of follow-up, active therapy resulted in a reduction of the combined rate of macrovascular and microvascular complications of diabetes, cardiovascular mortality, and total mortality. The ADVANCE-ON study was a post-trial 6-year follow-up of ADVANCE study participants. A beneficial effect on total mortality and cardiovascular mortality was found to persist in the patients previously assigned to perindopril and indapamide therapy despite no differences in blood pressure and other risk factors between the two study groups after termination of the randomized trial.
Article Details
Copyright © by Medical Education. All rights reserved.
References
2. ADVANCE Collaborative Group: Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 2008; 358: 2560-2572.
3. Kengne A.P., Czernichow S., Huxley R. et al.: Blood pressure variables and cardiovascular risk: new findings from ADVANCE. Hypertension 2009; 54: 399-404.
4. de Galan B.E., Zoungas S., Chalmers J. et al.: Cognitive function and risks of cardiovascular disease and hypoglycaemia in patients with type 2 diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial. Diabetologia 2009; 52: 2328-2336.
5. Zoungas S., de Galan B.E., Ninomiya T. et al.: Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: New results from the ADVANCE trial. Diabetes Care 2009; 32: 2068-2074.
6. Du X., Ninomiya T., de Galan B. et al.: Risks of cardiovascular events and effects of routine blood pressure lowering among patients with type 2 diabetes and atrial fibrillation: results of the ADVANCE study. Eur. Heart J. 2009; 30: 1128-1135.
7. Ninomiya T., Zoungas S., Neal B. et al.: Efficacy and safety of routine blood pressure lowering in older patients with diabetes: results from the ADVANCE trial. J. Hypertens. 2010; 28: 1141-1149.
8. van Dieren S., Kengne A.P., Chalmers J. et al.: Effects of blood pressure lowering on cardiovascular outcomes in different cardiovascular risk groups among participants with type 2 diabetes. Diabetes Res. Clin. Pract. 2012; 98: 83-90.
9. de Galan B.E., Perkovic V., Ninomiya T. et al.: Lowering blood pressure reduces renal events in type 2 diabetes. J. Am. Soc. Nephrol. 2009; 20: 883-892.
10. Heerspink H.J., Ninomiya T., Perkovic V. et al.: Effects of a fixed combination of perindopril and indapamide in patients with type 2 diabetes and chronic kidney disease. Eur. Heart J. 2010; 31: 2888-2896.
11. ADVANCE Echocardiography Substudy Investigators; ADVANCE Collaborative Group: Effects of perindopril-indapamide on left ventricular diastolic function and mass in patients with type 2 diabetes: the ADVANCE Echocardiography Substudy. J. Hypertens. 2011; 29: 1439-1447.
12. Zoungas S., Chalmers J., Neal B. et al.: Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N. Engl. J. Med. 2014; 371: 1392-1406.